Janux Therapeutics, Inc. JANX

Janux Therapeutics has recently dosed the first patient in its Phase 1 trial evaluating JANX013 in combination with JANX007 for metastatic castration-resistant prostate cancer, marking a new step in its clinical pipeline. This trial brings fresh attention to Janux Therapeutics’ prostate cancer platform, highlighting how the company is expanding its precision oncology approach into a difficult-to-treat setting. We’ll now examine how progress in this metastatic castration-resistant prostate...

Janux Therapeutics (JANX) just hit a clinical milestone, dosing the first patient in its Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer. This development is sharpening investor focus on this prostate cancer platform. The JANX share price has cooled in the near term, with a 1-month share price return down 9.6% and a 7-day move down 1.75%, even as the 90-day share price return is up 6.36% and the year-to-date share price return stands at 19.41%. Over a...

SAN DIEGO, September 14, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names got bullish bets and which lost their analyst backing.

In the past, Janux Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$21.97 million, or US$0.35 per share, compared with a net loss of US$33.86 million, or US$0.55 per share, a year earlier. For the first half of 2026, the company also reduced its net loss to US$46.33 million, or US$0.74 per share, signaling improving cost control and operating efficiency versus the prior-year period. We will now examine how Janux Therapeutics' reduced net loss and improving...

SAN DIEGO, August 06, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended June 30, 2026, and provided a business update.

Most small-cap biotech stocks are pure clinical bets. These three already have revenue on the books and insiders backing them with their own capital.

In late June 2026, Janux Therapeutics, Inc. was removed from several Russell growth and small-cap benchmarks, including the Russell 2000 Growth, 2500 Growth, Small Cap Comp Growth, 3000E Growth, and 3000 Growth indexes. This broad index removal matters because it can force index-tracking funds to rebalance, potentially changing who holds the stock and how it trades. Next, we’ll examine how Janux’s removal from multiple Russell growth indexes shapes the company’s investment narrative for...

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation. “Today’s news underscores our commitment to accelerate the development path of our growing BiTAC-TCE portfolio,” said Christoph Erkel, Ph.D., VERAXA’s Vice […] The post VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone appeared first on ExecE

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the most promising stocks on our list. TheFly reported on June 25 that Truist Securities initiated coverage of JANX with a Buy recommendation and a $26 price target, revised lower from $80. The […]

By Karen Roman Akari Therapeutics, Plc (Nasdaq: AKTX) said President and CEO Abizer Gaslightwala was part of a Virtual Investor “What This Means” interview highlighting the company’s first abstract acceptance […]

By Karen Roman VERAXA Biotech AG said it has a securities purchase agreement with an institutional investor for $27.5 million, separate to a $50 million share purchase agreement with Lincoln Park Capital Fund. The company also applied for a Nasdaq listing under the ticker symbol “VRXA” via a combination with Voyager Acquisition Corp. (Nasdaq: VACH) […] The post VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC appeared first on ExecEdge.